Abstract 518P
Background
Artificial Intelligence (AI) holds the promise to transform medicine during diagnosis, management and therapy of diseases. The AICCELERATE project will introduce an operational approach to develop AI-enabled digital solutions to improve medical processes by creating a digital twin. In our study, we performed the first pilot application of the AICCELERATE project at Bambino Gesù Children’s Hospital in Rome (OPBG). The aim of our study is to design a supervised machine learning (ML) model to predict time to surgery and time to diagnosis based (outputs) on time from admission to first consultation and imaging (inputs) in newly diagnosed pediatric patients.
Methods
We included pediatric patients with new diagnoses of brain tumors, treated in OPBG from December 2017 to December 2022. We collected from EHR the following data: age and sex, start and end date of the first admission, department of hospitalization, consultations and radiological imaging date, diagnosis, and surgery date.
Results
We included 48 patients with a pediatric brain tumor, with a mean age of 8.6 years. We used a multiple linear regression model, which does not require large datasets such as more complex models. Our analysis showed that delayed consulting and imaging led to a delayed diagnosis, with the consulting presenting a higher importance than the imaging. This result was validated by the model’s estimated regressors coefficients, with the consulting factor being assigned a larger weight β_C=1.81 than the imaging factor β_I=-0.33. Similarly, we observed that delayed consulting and imaging led to a delayed surgery, estimating a higher coefficient for the consulting β_C=0.71 than the one estimated for the imaging β_I=-0.06. While the ML model achieved a reasonable performance in both frameworks, the time to surgery was predicted with a lower MAE 4.45±0.87 compared to the diagnosis MAE of 6.74±0.95.
Conclusions
This preliminary study conducted in a small number of patients, suggests that decreasing time to consultation can shorten time to surgery in children with brain cancer. As the AICCELERATE is ongoing, more accurate models will be developed and will help to better understand how to optimize the journey of children with brain cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
612P - Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Presenter: fuxiang zhou
Session: Poster session 10
613P - Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster session 10
614P - Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Josep Tabernero
Session: Poster session 10
615P - The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer
Presenter: Satoshi Yuki
Session: Poster session 10
616P - Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) +/- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
Presenter: Tanios Bekaii-Saab
Session: Poster session 10
618P - Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
Presenter: Tae Won Kim
Session: Poster session 10
619P - Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study
Presenter: Guy Ungerechts
Session: Poster session 10
620P - A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data
Presenter: Giulia Martini
Session: Poster session 10
621P - The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial
Presenter: Alexej Ballhausen
Session: Poster session 10